drugset / Trial / NCT04893148
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus dulaglutide as intensification from basal insulin with metformin, in the absence of head-to-head trials.
Timeline
- Start
- 2020-05-26
- Primary completion
- 2021-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | 1.5 mg | — |
| Comparator | iGlarLixi | Unknown | 10 iu | — |
| Comparator | iGlarLixi | Unknown | 20 iu | — |